Sino Biopharmaceutical’s Innovative Cancer Drug TQB3142 Gains NMPA Approval for Clinical Trials

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.

Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3142, a novel PROTAC molecule targeting Bcl-xL protein for the treatment of malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug is designed to induce apoptosis in tumor cells with a reduced risk of platelet toxicity, offering a promising new treatment option in a field where no Bcl-xL inhibitors are currently approved worldwide.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It specializes in treatments for malignant tumors and operates with a market focus on China.

Average Trading Volume: 171,949,544

Technical Sentiment Signal: Buy

Current Market Cap: HK$132.9B

See more insights into 1177 stock on TipRanks’ Stock Analysis page.